Strasbourg

• A Efficacy and Safety Study of Trontinemab in Participants With Early Symptomatic Alzheimer’s Disease (MCI to Mild Dementia Due to AD) Recruiting
  2024-518008-33-00 5 2025-11-12 Early Symptomatic Alzheimer’s Disease (MCI to Mild Dementia due to AD)
• A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN) ( PREVAIL ) Recruiting
  2024-519345-30-00 5 2025-11-12 IgA nephropathy
• IFCT-2401 SPORADIC a multicenter randomized open label phase II study evaluating the efficacy and the tolerance of adding cemiplimab to Sequ … Recruiting
  2024-517316-29-00 4 2025-11-07 Unresectable stage III Non-Small Cell Lung Cancer
• A trial to see if ficerafusp alfa given with pembrolizumab can treat participants with head and neck cancer. Recruiting
  2024-519654-37-00 10 2025-11-07 Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.
• A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax P … Recruiting
  2024-517131-52-00 5 2025-11-03 Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lym
• A Phase 3 Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer’s Disease Recruiting
  2025-520747-32-00 5 2025-10-29 Mild to moderate Alzheimer’s Disease
• Testing ivonescimab in combination with standard chemotherapy in advanced or metastatic gastric and gastroesophageal adenocarcinoma patients Recruiting
  2025-520694-39-00 4 2025-10-24 Metastatic or locally advanced irresectable (stage IV) gastric cancer
• EASi-PROTKT™ - A study to test vicadrostat (BI 690517) taken together with empagliflozin in people with type 2 diabetes, high blood pressure … Recruiting
  2025-521188-11-00 5 2025-10-15 Type 2 diabetes
• Influence des caractéristiques morphologiques sur la pharmacocinétique et la toxicité du trastuzumab-déruxtécan chez des patients ayant un c … Recruiting
  2025-522656-68-00 6 2025-10-15 Metastatic breast cancers
• Clinical trial comparing induction treatment with EGFR-ADC MRG003 alone or in combination with the anti PD1 Pucotenlimab, followed by radioc … Recruiting
  2023-510558-18-00 4 2025-10-13 locally advanced head and neck squamous cell carcinoma
• SAFE-ESO_Phase II study evaluating safety and efficacy of Tislelizumab for elderly patients unfit for chemotherapy, with advanced esophageal … Recruiting
  2024-518358-17-00 4 2025-10-06 Squamous cell carcinoma of the esophagus
• INTER-EWING-1: International Clinical Research Programme to Improve Outcomes in Newly Diagnosed Ewing Sarcoma – Trial 1 Recruiting
  2024-511989-36-00 5 2025-09-24 Ewing Sarcoma
• ENGIC 01 - COLOSOTO: A single-arm phase II study evaluating 5-fluorouracil plus Panitumumab (anti-EGFR) and Sotorasib (KRAS G12C inhibitor) … Recruiting
  2024-514030-20-00 4 2025-08-29 colorectal cancer
• Safety and Efficacy of Intravenous Thrombolysis in Patients with Ischemic Stroke on Treatment with Direct Oral Anticoagulants: DO-IT – The D … Recruiting
  2024-515561-34-01 6 2025-08-04 Acute ischemic stroke with recent ingestion of direct oral anticoagula
• Phase 2 Study of ZN‑c3 in High-Grade Serous Ovarian Cancer Recruiting
  2022-502983-19-00 4 2025-07-31 High-Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cance
• A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esoph … Recruiting
  2023-509630-19-00 5 2025-07-31 Esophageal Squamous Cell Carcinoma (ESCC)
• Detection of tumour DNA in the blood of patients receiving standard therapy for hormone receptor-positive (HR+) HER2 low expression (HER2 lo … Recruiting
  2024-515349-41-00 4 2025-07-29 Metastatic Breast Cancer HR+, HER2-
• Study of Sacituzumab Govitecan Versus Standard of Care in Participants with Previously Treated Extensive Stage Small Cell Lung Cancer Recruiting
  2024-515884-69-00 5 2025-07-16 Extensive Stage Small Cell Lung Cancer (ES-SCLC)
• IFM2024-06 : A multi-center, open-label, phase 2 randomized study of elranatamab plus lenalidomide versus daratumumab plus lenalidomide as p … Recruiting
  2024-517325-43-00 4 2025-06-19 multiple myeloma
• A multicentre, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of BP1.4979 in adult p … Recruiting
  2024-517996-19-00 4 2025-06-19 Primary premature ejaculation
• Safety, efficacy, and pharmacokinetics of BNT327 in combination with chemotherapy and other investigational agents for lung cancer Recruiting
  2024-515764-31-00 10 2025-06-13 Non-small cell lung cancer
• A Phase 1/2a, First-in-human Study to Evaluate BMS-986470 in Healthy Volunteers and Participants with Sickle Cell Disease Recruiting
  2023-510283-12-00 7 2025-06-12 Sickle Cell Disease
• A phase 3 multicenter, randomised, prospective, open-label trial of fixed-duration (12 cycles) venetoclax/ obinutuzumab vs. fixed-duration ( … Recruiting
  2023-510294-34-00 5 2025-06-12 small lymphocytic lymphoma (SLL)
• Systemic antitumor treatment with or without pressurized intraperitoneal aerosol chemotherapy (PIPAC) for colon peritoneal metastases – a mu … Recruiting
  2024-514560-10-00 4 2025-06-12 Patients with newly diagnosed advanced peritoneal metastasis from colo

Showing 73–96 of 372 trials